GlobeNewswire
-
Greenwich LifeSciences Announces Acceptance of Abstracts at SABCS 2026
17/11/2026 -
Cognition Therapeutics Announces CTAD Poster Highlighting Screening Efficiencies with p-Tau217 in the Ongoing Phase 2 START Study
17/11/2026 -
Eikon Therapeutics Announces Clearance to Proceed with First-in-Human Phase 1/2 Study for Novel Androgen Receptor Antagonist EIK1006 in Advanced Metastatic Prostate Cancer
17/11/2026 -
Burning Rock Announces 2026 Annual General Meeting to be Held on December 22, 2026
17/11/2026 -
Biocomposites welcomes new clinical pathway for local infection management in severe pressure ulcers
17/11/2026 -
CancerVax Successfully Kills Cancer Cells in Landmark Test
17/11/2026 -
Cancer Research UK and Dewpoint Therapeutics partner to advance potential first-in-class MYC condensate modulator into clinical development
17/11/2026 -
ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline
17/11/2026 -
Commit Biologics announces final close of $60 million seed financing to advance complement-powered immune engagers toward the clinic
17/11/2026 -
Rapid Nutrition Announces SystemLS AI Mobile App to Accelerate International Growth and Create Recurring Subscription Revenue Opportunity
17/11/2026 -
Novartis Cosentyx® becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR)
17/11/2026 -
AriBio’s Oral AR1001 Meets Primary Efficacy Objective in Prespecified Monotherapy Population in Phase 3 POLARIS-AD Trial
17/11/2026 -
AGC Biologics Welcomes Multiple Cell Therapy Projects to New Yokohama Site
17/11/2026 -
Ziphius, une société de biotechnologie de premier plan spécialisée dans l’ARN auto-amplificateur, annonce aujourd’hui la nomination de M. Antoon Loomans au sein de son conseil d’administration
17/11/2026 -
Vivos Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Update
17/11/2026 -
New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026
17/11/2026 -
FDA approves Roche’s Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer
16/11/2026 -
IMDx Reports Third Quarter 2026 Results and Provides Corporate Update
16/11/2026 -
Cue Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights
16/11/2026
Pages